References
- Bellantone AR. 2014. Fundamentals of amorphous systems: thermodynamic aspects. Amorphous solid dispersions: theory and practice. New York (NY): Springer New York; p. 3–34.
- Bosselmann S, Williams RO. 2012. Route-specific challenges in the delivery of poorly water-soluble drugs. Formulating poorly water soluble drugs. New York (NY): Springer New York; p. 1–26.
- Cavallari C, Albertini B, Rodriguez L, Rabasco AM, Fini A. 2005. Release of indomethacin from ultrasound dry granules containing lactose-based excipients. J Control Release. 102:39–47.
- Chen H, Khemtong C, Yang X, Chang X, Gao J. 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 16:354–360.
- Couto AS, Vieira J, Florindo HF, Videira MA, Cabral-Marques HM. 2014. Characterisation of DM-β-cyclodextrin:prednisolone complexes and their formulation as eye drops. J Incl Phenom Macrocycl Chem. 80:155–164.
- Del Valle EMM. 2004. Cyclodextrins and their uses: a review. Process Biochem. 39:1033–1046.
- Elzoghby AO, Samy WM, Elgindy NA. 2012. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 157:168–182.
- Evans TW. 2002. Review article: albumin as a drug - biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 16:6–11.
- Frey FJ, Frey BM. 1984. Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Am J Kidney Dis. 3:339–348.
- Fukuda N, Higuchi N, Ohno M, Kenmochi H, Sekikawa H, Takada M. 1986. Dissolution behavior of prednisolone from solid dispersion systems with cyclodextrins and polyvinylpyrrolidone. Chem Pharm Bull. 34:1366–1369.
- Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. 2005. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 353:38–52.
- Ghuzlaan A, Al Omari MM, Al-Sou’od KA. 2009. Prednisone/cyclodextrin inclusion complexation: phase solubility, thermodynamic, physicochemical and computational analysis. J Solution Chem. 38:83–94.
- Graeser KA, Patterson JE, Zeitler JA, Rades T. 2010. The role of configurational entropy in amorphous systems. Pharmaceutics. 2:224–244.
- Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 86:1–12.
- Higuchi T. 1965. Chapter 4. Phase solubility studies. In: Reilly CN, editor. Advances in analytical chemistry and instrumentation. New York: Wiley-Interscience; p. 117–212.
- Huanbutta K, Sangnim T, Limmatvapirat S, Nunthanid J, Sriamornsak P. 2016. Design and characterization of prednisolone-loaded nanoparticles fabricated by electrohydrodynamic atomization technique. Chem Eng Res Des. 109:816–823.
- Huang Y, Dai W-G. 2014. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm Sin B. 4:18–25.
- Junghanns J-UAH, Müller RH. 2008. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 3:295–310.
- Kalepu S, Nekkanti V. 2015. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 5:442–453.
- Khoder M, Abdelkader H, ElShaer A, Karam A, Najlah M, Alany RG. 2016. Efficient approach to enhance drug solubility by particle engineering of bovine serum albumin. Int J Pharm. 515:740–748.
- Legler UF, Benet LZ. 1986. The effect of prednisone and hydrocortisone on the plasma protein binding of prednisolone in man. Eur J Clin Pharmacol. 30:51–55.
- Li X-S, Wang J-X, Shen Z-G, Zhang P-Y, Chen J-F, Yun J. 2007. Preparation of uniform prednisolone microcrystals by a controlled microprecipitation method. Int J Pharm. 342:26–32.
- Loftsson T, Jarho P, Masson M, Jarvinen T. 2005. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2:335–351.
- Owen IC. 2013. Salt forms: pharmaceutical aspects. Encyclopedia of pharmaceutical technology. 3rd ed. New York (NY): Taylor & Francis; p. 3177–3187.
- Peters T Jr. 1995. Chapter 3. Ligand binding by albumin. All about albumin. San Diego (CA): Academic Press; p. 76–132.
- Rocci ML, D’Ambrosio R, Johnson NF, JusKo WJ. 1982. Prednisolone binding to albumin and transcortin in the presence of cortisol. Biochem Pharmacol. 31:289–292.
- Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 59:603–616.
- Shi JH, Zhu YY, Wang J, Chen J, Shen YJ. 2013b. Intermolecular interaction of prednisolone with bovine serum albumin: spectroscopic and molecular docking methods. Spectrochim Acta A Mol Biomol Spectrosc. 103:287–294.
- Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res. 21:201–230.
- Urien S, Tillement J-P, Barré J. 2007. The significance of plasma-protein binding in drug research. Pharmacokinetic optimization in drug research. Helv Chim Acta. 189–197. DOI: 10.1002/9783906390437.ch12.
- Veiga MD, Cadorniga R, Lozana R. 1985. Thermal study of prednisolone polymorphs. Thermochim Acta. 96:111–115.
- Walzel P, Furuta T. 2011. Morphology and properties of spray-dried particles. Modern drying technology. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; p. 231–294.
- Yalkowsky SH, He Y. 2003. Handbook of aqueous solubility data. Boca Raton, FL: CRC Press.